Literature DB >> 12789286

The INK4a/ARF locus and melanoma.

E Sharpless1, Lynda Chin.   

Abstract

Inactivation of the INK4a/ARF (or CDKN2a) locus is a common and critical genetic event in the development of human and mouse melanoma. This locus engages the Rb and p53 tumor suppressor pathways through its capacity to encode two distinct gene products, p16(INK4a) and p14(ARF). This review highlights the body of evidence supporting a role for both p16(INK4a) and p14(ARF) in the suppression of melanoma, and speculates as to why this locus is preferentially targeted in this tumor type. In addition, the potential importance of these two pathways in mediating UV-induced melanoma genesis will be addressed via genetic and molecular evidence in the mouse.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12789286     DOI： 10.1038/sj.onc.1206461

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  72 in total

Review 1.  Pathways of oncogene-induced senescence in human melanocytic cells.

Authors:  Rajat Bansal; Mikhail A Nikiforov
Journal:  Cell Cycle       Date:  2010-07-03       Impact factor: 4.534

2.  GPR56 plays varying roles in endogenous cancer progression.

Authors:  Lei Xu; Shahinoor Begum; Marc Barry; Denise Crowley; Liquan Yang; Roderick T Bronson; Richard O Hynes
Journal:  Clin Exp Metastasis       Date:  2010-03-24       Impact factor: 5.150

3.  Effect of exogenous p16ink4a and hRb1 genes on cell cycle regulation of osteosarcoma cell.

Authors:  Xiang Liao; Shuhua Yang; Zengwu Shao; Jin Li; Yong Liu; Xiaoqian Xiong; Xin Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

Review 4.  Melanocyte receptors: clinical implications and therapeutic relevance.

Authors:  J Andrew Carlson; Gerald P Linette; Andrew Aplin; Bernard Ng; Andrzej Slominski
Journal:  Dermatol Clin       Date:  2007-10       Impact factor: 3.478

5.  Genetics of coronary artery disease: focus on genome-wide association studies.

Authors:  Linnea M Baudhuin
Journal:  Am J Transl Res       Date:  2009-03-05       Impact factor: 4.060

6.  Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.

Authors:  Chi Luo; Jinghao Sheng; Miaofen G Hu; Frank G Haluska; Rutao Cui; Zhengping Xu; Philip N Tsichlis; Guo-Fu Hu; Philip W Hinds
Journal:  Cancer Res       Date:  2013-05-06       Impact factor: 12.701

Review 7.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

8.  C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.

Authors:  D Zhuang; S Mannava; V Grachtchouk; W-H Tang; S Patil; J A Wawrzyniak; A E Berman; T J Giordano; E V Prochownik; M S Soengas; M A Nikiforov
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

9.  Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.

Authors:  Christian A Merkel; Rafael B da Silva Soares; Anna Carolina V de Carvalho; Daniela B Zanatta; Marcio C Bajgelman; Paula Fratini; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

Review 10.  Small molecules and targeted therapies in distant metastatic disease.

Authors:  P Hersey; L Bastholt; V Chiarion-Sileni; G Cinat; R Dummer; A M M Eggermont; E Espinosa; A Hauschild; I Quirt; C Robert; D Schadendorf
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.